Overview

High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure

Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Primary Aims 1. Evaluate the safety of high-dose spironolactone in combination of patiromer in acute decompensated heart failure patients. 2. Evaluate the efficacy of high-dose spironolactone in combination of patiromer in causing volume loss and symptom relief in patients with ADHF treated with high-dose spironolactone. Secondary Aims 1: Evaluate the effect of high-dose spironolactone on urinary sodium excretion and renal function.
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
Relypsa, Inc.
Treatments:
Mineralocorticoid Receptor Antagonists
Spironolactone